NRD
ACAD icon

Nebula Research & Development’s Acadia Pharmaceuticals ACAD Stock Holding History

Nebula Research & Development’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,571
Closed -$1.16M – 8
2025
Q2 		$1.16M Buy
53,571
+10,473
+24% +$195K 0.1% 350
2025
Q1 		$716K Sell
43,098
-6,939
-14% -$126K 0.07% 488
2024
Q4 		$918K Buy
50,037
+13,841
+38% +$223K 0.11% 322
2024
Q3 		$557K Sell
36,196
-64,082
-64% -$1.07M 0.07% 512
2024
Q2 		$1.63M Buy
100,278
+85,805
+593% +$1.38M 0.26% 101
2024
Q1 		$268K Buy
+14,473
New +$359K 0.06% 572

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nebula Research & Development's ACAD Position: Q3 2025 in Review

Nebula Research & Development sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 53,571 shares — an estimated $1.16M sold.

Nebula Research & Development first reported a position in ACAD in Q1 2024 and held it in 6 quarters. The position peaked at $1.63M in Q2 2024. 333 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Nebula Research & Development reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 53,571 Acadia Pharmaceuticals shares in Q3 2025, an estimated $1.16M.
  • Nebula Research & Development first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Nebula Research & Development's Acadia Pharmaceuticals position peaked at $1.63M in Q2 2024.
  • 333 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.